Biparametric MRI Associated With Higher False Positive Rate than Prostate-Specific Antigen for Prostate Cancer Screening
1. In this decision model analysis, biparametric MRI (bpMRI) testing led to an increased rate of...
Read More
Oncology
Long-term survival improved with use of tebentafusp for metastatic uveal melanoma
1. Across a median follow-up of 48.5 months, usage of tebentafusp for patients with metastatic...
Read More
Asciminib demonstrates superior efficacy for the treatment of CML in comparison to imatinib and second-generation TKIs
1. Asciminib demonstrated higher efficacy for the treatment of newly diagnosed CML than imatinib...
Read More
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
1. The event-free survival at 12 months was 83.7% in the neoadjuvant group vs 57.2% in the...
Read More
Short-term androgen deprivation therapy does not improve survival in patients receiving postoperative radiotherapy for prostate cancer
1. There was no significant difference in metastasis-free survival between the ADT and non-ADT...
Read More
Large language models (LLMs) demonstrated higher error rates compared to humans in a clinical oncology question bank
1. A comparative evaluation tested five publicly available LLMs on 2044 oncology questions,...
Read More
Perioperative Nivolumab in Resectable Lung Cancer
1. The 18-month event-free survival in the perioperative nivolumab group was 70.2% vs 50.0% in the...
Read More
Genomic data optimizes hematopoietic stem-cell transplantation (HSCT) timing for myelodysplastic syndromes (MDS) and improves patient outcomes
1. A decision support system using the Molecular International Prognostic Scoring System (IPSS-M)...
Read More
Novartis: ARV-766 is an androgen receptor degrader efficacious in treating metastatic prostate cancer
In patients with metastatic prostate cancer, ARV-766 treatment led to a greater than 50% reduction...
Read More
Positron emission tomography-guided treatment strategy may reduce need for chemotherapy for patients with HER2+ breast cancer
1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There...
Read More
Remote electronic patient reported outcomes may have limited feasibility in older patients with cancer
1. Among patients on anticancer treatment with malignancy who were 75 years of age or older, the...
Read More
Capecitabine or XELOX did not appear to improve overall survival when compared to PF in patients with advanced Esophageal Squamous Cell Carcinoma
1. Although capecitabine or XELOX did not improve overall survival when compared to PF, efficacy...
Read More
Trastuzumab Deruxtecan in Solid Tumours Harbouring HER2 Mutations
1. The objective response rate for trastuzumab deruxtecan was 29.4%. 2. Treatment-emergent adverse...
Read More
Minimal Residual Disease negativity after Autologous Hematopoietic Cell Transplantation with lenalidomide maintenance predicts better long-term outcomes in myeloma
1. Achieving Minimal Residual Disease (MRD) negativity at baseline before lenalidomide...
Read More
Promising results with new oncolytic virus targeted at advanced solid tumors
1. The use of recombinant L-IFN adenovirus in patients with recurrent or refractory advanced solid...
Read More
Higher national health expenditure correlates with better lymphoid malignancy survival rates in European countries.
1. Lymphoid malignancy survival rates in European countries correlate with natation health...
Read More
#VisualAbstract: Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo...
Read More
Afamitresgene autoleucel as an effective T-cell therapy for synovial sarcoma and liposarcoma
1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events...
Read More
Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer
1. Progression-free survival at 24 months was higher in the pembrolizumab versus...
Read More
The addition of cisplatin to standard-of-care radiation therapy does not appear to improve progression-free survival for patients with localized recurrent endometrial cancer.
1. For patients with localized endometrial cancer recurrence, adding cisplatin to radiation...
Read More